USANA Health Sciences (NYSE:USNA) Stock Rating Lowered by Zacks Research

USANA Health Sciences (NYSE:USNA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday, Zacks reports.

A number of other research analysts have also recently issued reports on USNA. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, September 21st. Two equities research analysts have rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

USANA Health Sciences Trading Down 3.3%

Shares of USANA Health Sciences stock opened at $13.86 on Wednesday. USANA Health Sciences has a 12 month low of $12.57 and a 12 month high of $23.59. The firm has a market capitalization of $256.05 million, a P/E ratio of -12.05, a P/E/G ratio of 2.17 and a beta of 0.66. The business has a fifty day simple moving average of $14.61 and a two-hundred day simple moving average of $17.99.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.22). The business had revenue of $205.89 million during the quarter, compared to analysts’ expectations of $217.42 million. USANA Health Sciences had a positive return on equity of 3.56% and a negative net margin of 2.34%. Analysts predict that USANA Health Sciences will post 0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue raised its stake in USANA Health Sciences by 79.3% during the third quarter. State of Alaska Department of Revenue now owns 11,950 shares of the company’s stock valued at $172,000 after buying an additional 5,284 shares during the last quarter. GAMMA Investing LLC boosted its holdings in USANA Health Sciences by 689.4% in the third quarter. GAMMA Investing LLC now owns 2,763 shares of the company’s stock worth $40,000 after acquiring an additional 2,413 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of USANA Health Sciences by 42.1% in the second quarter. Hsbc Holdings PLC now owns 31,960 shares of the company’s stock worth $673,000 after acquiring an additional 9,467 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences in the second quarter worth $17,295,080. Finally, Empowered Funds LLC purchased a new stake in shares of USANA Health Sciences in the second quarter worth $1,500,000. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences News Summary

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti edged its Q4 2026 EPS estimate up to $0.12 from $0.11, a modest improvement amid broader forecast reductions.
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” adding to the negative analyst sentiment. Zacks Research recommendations
• Negative Sentiment: Sidoti cut its FY2026 EPS estimate to $0.55 from $0.76 and its FY2027 estimate to $1.59 from $1.77. It also lowered forecasts for Q1, Q2, and Q3 2027, signaling weaker expected earnings.
• Negative Sentiment: Third-quarter sales fell 4%; USANA reported a loss of $0.11 per share, versus expectations for $0.11 in earnings, and revenue of $205.89 million, below the $217.42 million consensus. The company also lowered its fiscal 2026 outlook. USANA Q3 results and outlook

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.